… In the phase III CASTOR study in relapsed or refractory multiple myeloma, daratumumab,
bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical benefit versus Vd …

… is also approved in combination with bortezomib/melphalan/… combination with
bortezomib/thalidomide/dexamethasone in … of the phase 3 CASTOR study of daratumumab plus …

… has shown substantial efficacy with tolerable safety in relapsed or refractory … , dexamethasone,
and daratumumab versus carfilzomib and dexamethasone in patients with relapsed or …

… In randomized phase 3 studies—including patients with both newly diagnosed and relapsed
or refractory multiple myeloma—the addition of daratumumab to established combination …

… dexamethasone may also have had an impact on HRQoL. Finally, unlike bortezomib, side
effects with daratumumab … long-term treatment with daratumumab are likely to have remained …

… daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone
… frontline use of daratumumab plus lenalidomide and dexamethasone for patients with …

… MULTIPLE MYELOMA: CLINICAL AND EPIDEMIOLOGICAL Treatment with Daratumumab
Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic …

… After >3.5 years of median follow-up, the addition of daratumumab to Rd continued …
daratumumab plus bortezomib and dexamethasone (D-Vd) versus bortezomib and dexamethasone (…

… Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with … of
subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (…

… , the early relapse subgroup included pts with 1 prior line of therapy who relapsed <18
months after initiating their first line of therapy; pts with 1 prior line of therapy who relapsed ≥18 …